The emerging role of CD39/CD73 - adenosine axis in EGFR-mutated NSCLC growth, progression, and ICI resistance has allowed to define a further immune checkpoint as a potential strategy to develop targeted treatments (79, 80). This evidence concerns the gene NT5E and non-small cell lung carcinoma.